Overview

A Randomized, Double-blind, Placebo-controlled Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of JX2105 in Healthy Chinese Subjects

Status:
ENROLLING_BY_INVITATION
Trial end date:
2025-03-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the safety, tolerability after administration of single dose or multiple doses, and the pharmacokinetics (PK) of single and multiple doses of JX2105 in healthy study participants.
Phase:
PHASE1
Details
Lead Sponsor:
Zhejiang Jingxin Pharmaceutical Co., Ltd.